欢迎您访问中乔新舟官网!400-038-9959我的购物车(0)
您当前的位置:首页 > 产品中心
SW626人卵巢腺癌细胞 (STR鉴定)
英文名:SW626
货号:ZQ0534
价格:¥1700.00
加入购物车,提交订单信息之后,我们会第一时间与您取得联系!
推荐组合

SW626人卵巢腺癌细胞 (STR鉴定)

¥1700.00
+

SW626人卵巢腺癌细胞专用培养基

¥550.00

配套完培,组合使用,省时省力!

=

细胞套餐惊爆价

¥2250
加入购物车
  • 产品说明
  • 产品规格
  • 参考文献
  • STR鉴定

产品名称

SW626人卵巢腺癌细胞

货号

ZQ0534

产品介绍

SW626 [SW-626,SW626]是一种人卵巢腺癌细胞系,由A. Leibovitz于1974年1月在德克萨斯州Temple的Scott and White诊所从一名46岁女性高加索人的卵巢囊腺癌手术标本中分离得到。尽管最初认为SW 626细胞系起源于卵巢,但最近的一份报告表明SW 626细胞系可能来源于原发性结肠腺癌的卵巢转移(PubMed=)10433623)

SW626细胞系被广泛用于各种生物医学研究,包括药物筛选、癌症生物学研究以及作为肿瘤模型进行病理学研究。此外,它们也被用于研究肿瘤微环境、肿瘤转移机制和肿瘤免疫反应。

种属

性别/年龄

/46岁

组织

卵巢

疾病

腺癌

细胞类型

肿瘤细胞 

形态学

上皮的

生长方式

贴壁

换液频率

2~3次/周 

培养基和添加剂(默认)

DMEM/F12(中乔新舟 货号:ZQ-600+10%FBS(中乔新舟 货号:ZQ0500+1%双抗(中乔新舟   货号:CSP006

注意默认方案培养条件:95%空气,5%CO2;37℃

培养方案B(可选)

L-15(中乔新舟  货号:ZQ-1100+10%FBS(中乔新舟  货号:ZQ500-A+1%双抗(中乔新舟   货号:CSP006

注意B方案培养条件:100%空气;37℃

推荐默认完全培养基货号

ZM0534

B方案完全培养基货号

ZM0534-B

生物安全等级

BSL-1

STR位点信息

Amelogenin: X

CSF1PO: 11
D13S317: 11
D16S539: 11
D5S818: 12
D7S820: 10,12
TH01: 9.3
TPOX: 8
vWA: 17,18
D3S1358: 15,17
D21S11: 27,29
D18S51: 14
Penta_E: 7,11
Penta_D: 9,13
D8S1179: 11
FGA: 21,23
D19S433: 14
D2S1338: 25

默认方案培养条件

95%空气,5%CO2;37℃

抗原表达/受体表达

***

基因表达

***

保藏机构

ATCC; HTB-78 ECACC; 91091203

供应限制

仅供科研使用

货号

ZQ0534

发货规格

活细胞:T25培养瓶*1瓶或者1ml 冻存管*1支(细胞量约为5 x 10^5 cells/vial)二选一

发货形式

活细胞:常温运输;冻存管:干冰运输

储存温度

活细胞:培养箱;冻存管:液氮罐

产地

中国

供应限制

仅供科研使用


1、PubMed=327080; DOI=10.1093/jnci/59.1.221
Fogh J., Fogh J.M., Orfeo T.
One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice.
J. Natl. Cancer Inst. 59:221-226(1977)


2、PubMed=833871; DOI=10.1093/jnci/58.2.209
Fogh J., Wright W.C., Loveless J.D.
Absence of HeLa cell contamination in 169 cell lines derived from human tumors.
J. Natl. Cancer Inst. 58:209-214(1977)


3、PubMed=6220172
Dracopoli N.C., Fogh J.
Polymorphic enzyme analysis of cultured human tumor cell lines.
J. Natl. Cancer Inst. 70:469-476(1983)


4、PubMed=6582512; DOI=10.1073/pnas.81.2.568
Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.
Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984)


5、PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)


6、PubMed=9698466; DOI=10.1006/gyno.1998.5039
Maxwell G.L., Risinger J.I., Tong B., Shaw H., Barrett J.C., Berchuck A., Futreal P.A.
Mutation of the PTEN tumor suppressor gene is not a feature of ovarian cancers.
Gynecol. Oncol. 70:13-16(1998)


7、PubMed=10433623; DOI=10.1093/jnci/91.15.1327
Furlong M.T., Hough C.D., Sherman-Baust C.A., Pizer E.S., Morin P.J.
Evidence for the colonic origin of ovarian cancer cell line SW626.
J. Natl. Cancer Inst. 91:1327-1328(1999)


8、PubMed=11314036; DOI=10.1038/sj.onc.1204211
Forgacs E., Wren J.D., Kamibayashi C., Kondo M., Xu X.L., Markowitz S.D., Tomlinson G.E., Muller C.Y., Gazdar A.F., Garner H.R., Minna J.D.
Searching for microsatellite mutations in coding regions in lung, breast, ovarian and colorectal cancers.
Oncogene 20:1005-1009(2001)


9、PubMed=12068308; DOI=10.1038/nature00766
Davies H., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S., Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S., Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.
Mutations of the BRAF gene in human cancer.
Nature 417:949-954(2002)


10、PubMed=20106510; DOI=10.1016/j.ygyno.2009.12.002
Byron S.A., Gartside M.G., Wellens C.L., Goodfellow P.J., Birrer M.J., Campbell I.G., Pollock P.M.
FGFR2 mutations are rare across histologic subtypes of ovarian cancer.
Gynecol. Oncol. 117:125-129(2010)


11、PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)


12、PubMed=23415752; DOI=10.1016/j.molonc.2012.12.007
Stordal B., Timms K., Farrelly A., Gallagher D., Busschots S., Renaud M., Thery J., Williams D., Potter J., Tran T., Korpanty G., Cremona M., Carey M.S., Li J., Li Y., Aslan O., O'Leary J.J., Mills G.B., Hennessy B.T.
BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.
Mol. Oncol. 7:567-579(2013)


13、PubMed=25846456; DOI=10.3892/ijo.2015.2951
Takenaka M., Saito M., Iwakawa R., Yanaihara N., Saito M., Kato M., Ichikawa H., Shibata T., Yokota J., Okamoto A., Kohno T.
Profiling of actionable gene alterations in ovarian cancer by targeted deep sequencing.
Int. J. Oncol. 46:2389-2398(2015)


14、PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)


15、PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)


16、PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)


17、PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)


18、PubMed=30971826; DOI=10.1038/s41586-019-1103-9
Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M., Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R., Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P., van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L., Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Nature 568:511-516(2019)


19、PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

暂无相关产品!
公司简介 / Company profile
上海中乔新舟生物科技有限公司
Shanghai Zhong Qiao Xin Zhou Biotechnology Co.,Ltd.
           上海中乔新舟生物科技有限公司(官网:www.zqxzbio.com)成立于2011年,历经...
联系我们 / Contact
电 话:021-56760357;021-56760351
传 真:
邮 箱:sales@zqxzbio.com
邮 编:200439
地 址:上海市宝山区长江南路180号
Copyright © 2014 ZQXZBIO All rights reserved.
技术支持:中乔新舟沪ICP备14008091号